Tyrosine Kinase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
(New page: {| class="wikitable" border="1" width="40%" style="text-align:center" |- ! colspan="16" align="center"| Cyclooxygenase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmac...) |
|||
| (33 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {| class="wikitable" border=" | + | {| class="wikitable" border="0" width="100%" style="text-align:center" |
|- | |- | ||
| - | ! colspan=" | + | ! colspan="9" align="center"| Tyrosine Kinase Inhibitor [[Pharmacokinetics]] |
| + | |- | ||
| + | ! colspan="1" align="center"| | ||
| + | ! colspan="2" align="center"| [[VEGFR]] & KIT Inhibitors | ||
| + | ! colspan="3" align="center"| [[EGFR]] Inhibitors | ||
| + | ! colspan="3" align="center"| BCR-Abl Inhibitor | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| - | ! | + | ! [[Sunitinib]]<br/>(Sutent) |
| - | ! | + | ! [[Sorafenib]]<br/>(Nexavar) |
| - | ! | + | ! [[Erlotinib]]<br/>(Tarceva) |
| - | ! | + | ! [[Gefitinib]]<br/>(Iressa) |
| - | ! | + | ! [[Lapatinib]]<br/>(Tykerb) |
| - | ! | + | ! [[Imatinib]]<br/>(Gleevec) |
| - | + | ! [[Nilotinib]]<br/>(Tasigna) | |
| - | + | ! [[Dasatinib]]<br/>(Sprycel) | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | ! [[ | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | ! [[ | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) |
| - | ! | + | ! 8 |
| - | ! | + | ! 8.3 |
| - | ! | + | ! 2.0 |
| - | ! | + | ! 5.4 |
| - | ! | + | ! 4 |
| - | ! | + | ! 3.7 |
| - | ! | + | ! 3.0 |
| - | ! | + | ! 1.0 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) |
| - | ! | + | ! 24.6 |
| - | ! | + | ! 460 |
| - | ! | + | ! 69.6 |
| - | ! | + | ! 130 |
| - | ! | + | ! 115 |
| - | ! | + | ! 2070 |
| - | ! | + | ! 411 |
| - | ! | + | ! 124 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) |
| - | ! | + | ! Variable |
| - | ! | + | ! 29-49 |
| - | ! | + | ! 99 |
| - | ! | + | ! 59 |
| - | ! | + | ! Variable |
| - | ! | + | ! 98 |
| - | ! | + | ! 30 |
| - | ! | + | ! 20 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) |
| - | ! | + | ! 95 |
| - | ! | + | ! 99 |
| - | ! | + | ! 93 |
| - | ! | + | ! 90 |
| - | ! | + | ! 99 |
| - | ! | + | ! 95 |
| - | ! | + | ! 98 |
| - | ! | + | ! 96 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) |
| - | ! | + | ! 83 |
| - | ! | + | ! 29 |
| - | ! | + | ! 9.4 |
| - | ! | + | ! 26.9 |
| - | ! | + | ! 9.6 |
| - | ! | + | ! 26.6 |
| - | ! | + | ! 16.0 |
| - | ! | + | ! 3.3 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) |
| - | ! | + | ! 1921 |
| - | ! | + | ! 11040 |
| - | ! | + | ! 20577 |
| - | ! | + | ! 3850 |
| - | ! | + | ! 1429 |
| - | ! | + | ! 4760 |
| - | ! | + | ! 10052 |
| - | ! | + | ! 461 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
! Dosage (mg) | ! Dosage (mg) | ||
| - | ! | + | ! 50 |
| - | ! | + | ! 50 |
| - | ! | + | ! 150 |
| - | ! | + | ! 250 |
| - | ! | + | ! 100 |
| - | ! | + | ! 400 |
| - | ! | + | ! 200 |
| - | ! | + | ! 200 |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|- | |- | ||
! Metabolism | ! Metabolism | ||
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
|} | |} | ||
| + | For Pharmacokinetic Data References, see: [[Treatments:TYKI References|References]] | ||
Current revision
| Tyrosine Kinase Inhibitor Pharmacokinetics | ||||||||
|---|---|---|---|---|---|---|---|---|
| VEGFR & KIT Inhibitors | EGFR Inhibitors | BCR-Abl Inhibitor | ||||||
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | Erlotinib (Tarceva) | Gefitinib (Iressa) | Lapatinib (Tykerb) | Imatinib (Gleevec) | Nilotinib (Tasigna) | Dasatinib (Sprycel) |
| Tmax (hr) | 8 | 8.3 | 2.0 | 5.4 | 4 | 3.7 | 3.0 | 1.0 |
| Cmax (ng/ml) | 24.6 | 460 | 69.6 | 130 | 115 | 2070 | 411 | 124 |
| Bioavailability (%) | Variable | 29-49 | 99 | 59 | Variable | 98 | 30 | 20 |
| Protein Binding (%) | 95 | 99 | 93 | 90 | 99 | 95 | 98 | 96 |
| T1/2 (hr) | 83 | 29 | 9.4 | 26.9 | 9.6 | 26.6 | 16.0 | 3.3 |
| AUC (ng/ml/hr) | 1921 | 11040 | 20577 | 3850 | 1429 | 4760 | 10052 | 461 |
| Dosage (mg) | 50 | 50 | 150 | 250 | 100 | 400 | 200 | 200 |
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) |
For Pharmacokinetic Data References, see: References
